PARP inhibitors and quality of life in ovarian cancer

Lancet Oncol. 2018 Aug;19(8):1012-1014. doi: 10.1016/S1470-2045(18)30435-2. Epub 2018 Jul 17.

Authors

Daisuke Aoki¹, Tatsuyuki Chiyoda²

Affiliations

¹ Department of Obstetrics and Gynecology, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan. Electronic address: aoki@z7.keio.jp.
² Department of Obstetrics and Gynecology, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan.

PMID: 30026001
DOI: 10.1016/S1470-2045(18)30435-2

No abstract available

Publication types

Comment

MeSH terms

Double-Blind Method
Female
Humans
Indazoles
Neoplasm Recurrence, Local
Ovarian Neoplasms*
Piperidines
Poly(ADP-ribose) Polymerase Inhibitors*
Quality of Life

Substances

Indazoles
Piperidines
Poly(ADP-ribose) Polymerase Inhibitors
niraparib